My simple answer is that ALS patients are willing to accept greater risk because we know what is behind door number two.

Thank you, Mr. Chairman. My pleasure to introduce Dr. Peggy Plews-Ogan.

I have been working on this for most of the five-years I have been here in the Senate.

This is long overdue.

My simple answer is that ALS patients are willing to accept greater risk because we know what is behind door number two.

That is why we need the formality of PPA.

We should be that leading edge and we should have a system that accommodates it.

Patients deserve a promising pathway at the FDA.

We should be that leading edge and we should have a system that accommodates it.

The Promising Pathway Act is a commonsense step to give the FDA the flexibility it needs to serve Americans with these most trying diseases.

I call up my amendment No. 1182 and ask that it be reported by number. The PRESIDING OFFICER. The clerk will report. The senior assistant legislative clerk read as follows: The Senator from Indiana [Mr. Braun], for himself and others…

However, millions of Americans with these diseases still lack any FDA approved treatments.

However, millions of Americans with these diseases still lack any FDA approved treatments.

And I ask for the yeas and nays. The PRESIDING OFFICER. The question is on agreeing to the amendment. Is there a sufficient second? There appears to be a sufficient second. The clerk will call the roll. The senior assistant legislative…

The time is not the right amount of time, and the children are being ignored in this and it shouldn't be that way.

Patients deserve a promising pathway at the FDA.

The Promising Pathway Act is a commonsense step to give the FDA the flexibility it needs to serve Americans with these most trying diseases.

The fact that we haven't done that in 20-some years makes this very much an academic discussion.